Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men who have been diagnosed with Parkinson's disease at a mild to moderate stage (up to stage 3 on a scale doctors use called the Hoehn and Yahr scale)
- People aged between 51 and 70 years old
- People with a body weight considered to be in the normal range (BMI between 18.5 and 24.9)
- People with lower than normal vitamin D levels in their blood (a blood test result below 30 ng/ml)
- People currently being treated with a medication called Levodopa for their Parkinson's disease
Who may not be able to join:
- People who are already taking vitamin D3 supplements
- People currently using medications or substances that are known to affect brain activity or brainwave patterns, such as sedatives, antidepressants, antipsychotics, or alcohol
- People currently living with certain neurological conditions, such as migraines or epilepsy
- People with heart or blood vessel conditions, such as a history of heart attack, high blood pressure, irregular heartbeat, or heart failure
- People with breathing conditions such as asthma or chronic obstructive pulmonary disease (a long-term lung condition)
- People with psychiatric conditions such as schizophrenia, major depression, bipolar disorder, or severe dementia
- People whose blood tests show high calcium levels, reduced kidney function, liver disease, or uncontrolled thyroid or blood sugar conditions
- People who currently smoke
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in absolute power in alpha, beta, theta, and delta frequency bands from baseline to 8 weeks; Change in relative power in alpha, beta, theta, and delta frequency bands from baseline to 8 weeks; Change in peak power frequency in alpha, beta, theta, and delta bands from baseline to 8 weeks; Change in median power frequency from baseline to 8 weeks; Change in spectral edge frequency (SEF 90) from baseline to 8 weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.